Chronic Urticaria Drug Landscape

Novartis confirmed on 2026-11-12 that Rhapsido had US approvals for CSU and symptomatic dermographism; leadership here refers to regulatory progress, without a cross-trial efficacy ranking.

Novartis reported on 2026-11-12 that 46.8% of symptomatic dermographism patients originally assigned Rhapsido had a complete or partial response at Week 52 in RemIND.

Celldex said on 2026-11-05 that it expected to submit a CSU application for barzolvolimab in 2027; filing and acceptance could change the regulatory field.

Chronic Urticaria Drug Landscape

CSU and chronic inducible urticaria (CIndU) are separate populations; response rates across subtypes or trials do not establish an efficacy ranking.

Competitive landscape

AssetCompanyMechanism / routeStageIndicationTrial identifierDealLatest developmentSource
Rhapsido / remibrutinibNovartisSwitzerlandBTK inhibitorOralUS approved: CSU / symptomatic dermographismCSU; subtype-specific CIndU——RemIND: 25 mg twice daily; SD Week 1 response 41.8% vs 19.2%; original-treatment Week 52 response 46.8%novartis.com
Dupixent / dupilumabSanofi / RegeneronFrance / USIL-4Rα antibodySubcutaneousUS approvedCSU, age 2+, symptomatic despite H1 antihistamines——Label includes age 2+; prior age-12 threshold is supersededdailymed.nlm.nih.gov
Xolair / omalizumabRoche / Genentech / NovartisSwitzerland / USAnti-IgE antibodySubcutaneousUS approvedCSU——Approved anti-IgE comparatorgene.com
barzolvolimabCelldexUSAnti-KIT antibodySubcutaneousPhase 3 results reported; filing plannedCSU; ColdU / dermographism——CSU Phase 3 endpoints met; 2027 filing plannedir.celldex.com
CUE-221 / UB-221Cue / Ascendant / Genesis; originated at United BioPharmaTaiwan origin / China trial / US licenseeAnti-IgE antibodySubcutaneousPhase 2 results; Phase 2b/3 plannedCSU——145 in China Phase 2; no planned statistical comparison with Xolaircuebiopharma.gcs-web.com
lesigercept / YH35324YuhanSouth KoreaIgE-trap fusion proteinSubcutaneousPhase 2CSUjRCT2031260326—Phase 2 registered in Japan; registration is not marketing approvaljrct.mhlw.go.jp
JSONCSV

Taiwan and Asia

Taiwan-origin UB-221 is being developed as CUE-221 outside Greater China; Genesis retains China, Hong Kong, Macau and Taiwan rights. The China Phase 2 enrolled 145 participants; omalizumab was an active comparator without planned statistical testing. Korea’s Yuhan also has a CSU Phase 2 registered in Japan.